menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Sellas Reports Positive Ph 2a Data For SLS009, Zanubrutinib In DLBCL

    GLOBENEWSWIRE

    Prelude Therapeutics Presents Phase 1 Results of PRT2527 Study

    GLOBENEWSWIRE

    BeiGene Highlights Waldenström’s Macroglobulinemia At IWWM 2024

    BUSINESSWIRE

    BeiGene Announces Updates to Commercial Leadership Team

    BUSINESSWIRE

    BeiGene To Present BRUKINSA Plus Venetoclax CLL SLL Data

    BUSINESSWIRE

    BeiGene & NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA

    BUSINESSWIRE

    Glenmark unit ties up with BeiGene to market cancer drugs in India

    MONEYCONTROL

    First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia

    BUSINESSWIRE

    US FDA approves expanded use of BeiGene`s blood cancer drug

    REUTERS

    BeiGene Announces FDA Accelerated Approval of BRUKINSA

    BUSINESSWIRE

    FDA Confirms Paragraph IV Patent Litigation for Zanubrutinib Capsules

    FDA

    BeiGene`s Brukinsa (zanubrutinib) Receives Approval in Europe

    EMA

    Singapore’s Drug List adds BeiGene`s Zanubrutinib for multiple indications

    BIOSPECTRUM ASIA

    BeiGene Receives European Commission Approval for BRUKINSA

    BUSINESSWIRE

    BeiGene touts Brukinsa data, Cellectis compares CAR-T to CDMO CAR-T

    ENDPTS

    BRUKINSA® Receives Positive Recommendation from NICE in U.K.

    BUSINESSWIRE

    BeiGene Receives Positive CHMP Opinion for BRUKINSA in Follicular Lymphoma

    BUSINESSWIRE

    Zanubrutinib Sustains Response Vs Ibrutinib in Waldenström Macroglobulinemia

    ONCLIVE

    FDA Accepts Zanubrutinib Application For New Follicular Lymphoma Indication

    PRESS RELEASE

    BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication

    BUSINESSWIRE

    Long-Term ROSEWOOD Data Confirm Efficacy of Zanubrutinib Plus

    ONCOLIVE

    AbbVie`s Imbruvica-Brukinsa patent suit may have merit: expert

    FIERCE PHARMA

    Zanubrutinib Plus Obinutuzumab and Venetoclax Induces High Undetectable MRD

    ONCLIVE

    BeiGene Highlights Significant BRUKINSA Data at 17th International Conference

    PRESS RELEASE

    BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics

    BUSINESSWIRE

    BeiGene offers free Brukinsa to patients in low-income countries

    FIERCE PHARMA

    China’s NMPA approves BeiGene’s Brukinsa to treat WM, CLL/ SLL

    GLOBENEWSWIRE

    BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

    BUSINESSWIRE

    BeiGene doubles sales on Brukinsa, tislelizumab strength

    FIERCE PHARMA

    BeiGene`s Brukinsa (zanubrutinib) Approved In Europe

    EMA

    BRUKINSA Receives Marketing Authorization for CLL & MZL in Great Britain by MHRA

    PRESS RELEASE

    BeiGene granted US nod for Brukinsa in chronic lymphocytic leukaemia

    BUSINESSWIRE

    BeiGene wants greater blending of mental health into cancer care

    FIERCEPHARMA

    BeiGene`s Brukinsa shows PFS benefit of 35% over Imbruvica

    BUSINESSWIRE

    BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022

    PRESS RELEASE

    BeiGene Receives European Commission Approval for BRUKINSA

    BUSINESSWIRE

    BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib)

    PRESS RELEASE

    BeiGene gains further approvals for Brukinsa in Latin America

    THEPHARMALETTER

    BeiGene Expands Reach of its Innovative BTK Inhibitr Recent Regulatory Approvals

    PRESS RELEASE

    BeiGene touts Brukinsa-Imbruvica head-to-head win in CLL

    FIERCEPHARMA

    UK NICE recommends zanubrutinib for Waldenstrom’s macroglobulinaemia

    PHARMACEUTICAL-TECHNOLOGY

    NICE says yes to BeiGene’s Brukinsa after Scottish nay

    PHARMAPHORUM

    NICE signs off on BeiGene`s Brukinsa for blood cancer disorder

    FIERCEPHARMA

    NICE Recommends BeiGene’s BRUKINSA for Waldenström’s Macroglobulinemia

    BUSINESSWIRE

    FDA extends BeiGene`s Brukinsa review in key leukemia realm

    FIERCEPHARMA

    BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

    BUSINESSWIRE

    BeiGene Announces BRUKINSA Approval in Uruguay in MCL, MZL, and WM

    BUSINESSWIRE

    BRUKINSA Demonstrates Superior ORR Vs Ibrutinib in Analysis of ALPINE Trial

    BUSINESSWIRE

    BeiGene and Medison Announce Approval and National Reimbursement for BRUKINSA

    BUSINESSWIRE

    BeiGene Ireland`s Brukinsa (zanubrutinib) Receives Approval in Europe

    EMA

    BeiGene Announces Health Canada Approval for BRUKINSA in r/r MZL

    BUSINESSWIRE

    FDA Accepts BeiGene`s sNDA for BRUKINSA (zanubrutinib) in CLL

    BUSINESSWIRE

    BeiGene Announces Approval for BRUKINSA by Swissmedic for WM

    BUSINESSWIRE

    Supplemental NDA accepted for leukaemia treatment in China

    PHARMAFILE

    NMPA Accpets BeiGene`s sNDA for BRUKINSA in Waldenström’s Macroglobulinemia

    BUSINESSWIRE

    BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL)

    PRESS RELEASE

    BeiGene Announces Inclusion in the China National Reimbursement Drug List

    BUSINESSWIRE

    Saudi FDA approves BeiGene & NewBridge Pharma’s Brukinsa to treat r/r MCL

    PHARMABIZ

    BeiGene and NewBridge Pharma Announce Approval in Saudi Arabia of BRUKINSA®

    BUSINESSWIRE

    BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.